Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1997;75(5):397–415.

Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.

PMCID: PMC2487011  PMID: 9447774

Abstract

alpha 1-Antitrypsin (AAT) deficiency, also known as alpha 1-antiprotease inhibitor deficiency, is a disease caused by genetically determined AAT deficiency. It occurs as a result of inheritance of two protease inhibitor (PI) deficiency alleles from the AAT gene locus (designated PI) on chromosomal segment 14q32.1. The most common deficiency allele is PI*Z and a large majority of individuals with severe AAT deficiency are PI type ZZ. The disease occurs predominantly in white persons of European origin and its frequency in Europe and North America is comparable to that of cystic fibrosis (1 in 2000 to 1 in 7000.) Persons with AAT deficiency may have no clinical manifestations. Chronic obstructive pulmonary disease (COPD) with a high frequency of panacinar emphysema is the most prevalent clinical disorder associated with AAT deficiency and the most frequent cause of disability and death. Tobacco smoking is the major risk factor for developing COPD, which generally begins by the third decade of life, much earlier than "usual" COPD that occurs in AAT-replete individuals. Liver disease, the second most frequent clinical manifestation of AAT deficiency, typically presents as cholestasis in infancy but is usually not severe and generally remits by adolescence. Chronic liver disease develops infrequently, although AAT deficiency is the commonest cause of chronic liver disease in childhood. Cirrhosis and carcinoma of the liver affect at least 25% of AAT-deficient adults over the age of 50 years. AAT deficiency appears to be widely underdiagnosed and based on predicted gene frequencies even in the most intensely studied populations, only a small proportion of those predicted to have AAT deficiency have been diagnosed. Human AAT is available in limited quantity for augmentation therapy. This Memorandum summarizes the discussions and recommendations made by participants at a WHO meeting held in Geneva on 18-20 March 1996 to review existing knowledge about this highly prevalent genetic disorder, develop a strategy for enhancing awareness of it among health-care-givers and the general public, and explore new case-finding and disease-prevention strategies.

Full text

PDF
397

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbey D. E., Hwang B. L., Burchette R. J., Vancuren T., Mills P. K. Estimated long-term ambient concentrations of PM10 and development of respiratory symptoms in a nonsmoking population. Arch Environ Health. 1995 Mar-Apr;50(2):139–152. doi: 10.1080/00039896.1995.9940891. [DOI] [PubMed] [Google Scholar]
  2. Bakke P. S., Baste V., Hanoa R., Gulsvik A. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax. 1991 Dec;46(12):863–870. doi: 10.1136/thx.46.12.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berg N. O., Eriksson S. Liver disease in adults with alpha-1 -antitrypsin deficiency. N Engl J Med. 1972 Dec 21;287(25):1264–1267. doi: 10.1056/NEJM197212212872502. [DOI] [PubMed] [Google Scholar]
  4. Brantly M., Nukiwa T., Crystal R. G. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988 Jun 24;84(6A):13–31. doi: 10.1016/0002-9343(88)90154-4. [DOI] [PubMed] [Google Scholar]
  5. Cammarata S. K., Stone C. L., Carey J. L., Eichenhorn M. S. Failure to achieve adequate serum levels with monthly replacement therapy in alpha 1-antitrypsin deficiency. Chest. 1994 Aug;106(2):651–652. doi: 10.1378/chest.106.2.651. [DOI] [PubMed] [Google Scholar]
  6. Canonico A. E., Conary J. T., Meyrick B. O., Brigham K. L. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits. Am J Respir Cell Mol Biol. 1994 Jan;10(1):24–29. doi: 10.1165/ajrcmb.10.1.8292378. [DOI] [PubMed] [Google Scholar]
  7. Carrell R. W., Jeppsson J. O., Laurell C. B., Brennan S. O., Owen M. C., Vaughan L., Boswell D. R. Structure and variation of human alpha 1-antitrypsin. Nature. 1982 Jul 22;298(5872):329–334. doi: 10.1038/298329a0. [DOI] [PubMed] [Google Scholar]
  8. Carrell R. W., Stein P. E. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol Chem Hoppe Seyler. 1996 Jan;377(1):1–17. doi: 10.1515/bchm3.1996.377.1.1. [DOI] [PubMed] [Google Scholar]
  9. Casolaro M. A., Fells G., Wewers M., Pierce J. E., Ogushi F., Hubbard R., Sellers S., Forstrom J., Lyons D., Kawasaki G. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol (1985) 1987 Nov;63(5):2015–2023. doi: 10.1152/jappl.1987.63.5.2015. [DOI] [PubMed] [Google Scholar]
  10. Cox D. W., Billingsley G. D., Mansfield T. DNA restriction-site polymorphisms associated with the alpha 1-antitrypsin gene. Am J Hum Genet. 1987 Nov;41(5):891–906. [PMC free article] [PubMed] [Google Scholar]
  11. Cox D. W., Billingsley G. D. Rare deficiency types of alpha 1-antitrypsin: electrophoretic variation and DNA haplotypes. Am J Hum Genet. 1989 Jun;44(6):844–854. [PMC free article] [PubMed] [Google Scholar]
  12. Cox D. W., Smyth S. Risk for liver disease in adults with alpha 1-antitrypsin deficiency. Am J Med. 1983 Feb;74(2):221–227. doi: 10.1016/0002-9343(83)90615-0. [DOI] [PubMed] [Google Scholar]
  13. Cox D. W., Woo S. L., Mansfield T. DNA restriction fragments associated with alpha 1-antitrypsin indicate a single origin for deficiency allele PI Z. Nature. 1985 Jul 4;316(6023):79–81. doi: 10.1038/316079a0. [DOI] [PubMed] [Google Scholar]
  14. Edmonds B. K., Hodge J. A., Rietschel R. L. Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature. Pediatr Dermatol. 1991 Dec;8(4):296–299. doi: 10.1111/j.1525-1470.1991.tb00937.x. [DOI] [PubMed] [Google Scholar]
  15. Engh R. A., Huber R., Bode W., Schulze A. J. Divining the serpin inhibition mechanism: a suicide substrate 'springe'? Trends Biotechnol. 1995 Dec;13(12):503–510. doi: 10.1016/S0167-7799(00)89013-7. [DOI] [PubMed] [Google Scholar]
  16. Eriksson S., Carlson J., Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986 Mar 20;314(12):736–739. doi: 10.1056/NEJM198603203141202. [DOI] [PubMed] [Google Scholar]
  17. Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl. 1965;432:1–85. [PubMed] [Google Scholar]
  18. Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl. 1965;432:1–85. [PubMed] [Google Scholar]
  19. Garver R. I., Jr, Chytil A., Courtney M., Crystal R. G. Clonal gene therapy: transplanted mouse fibroblast clones express human alpha 1-antitrypsin gene in vivo. Science. 1987 Aug 14;237(4816):762–764. doi: 10.1126/science.3497452. [DOI] [PubMed] [Google Scholar]
  20. Gishen P., Saunders A. J., Tobin M. J., Hutchison D. C. Alpha 1-antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. Clin Radiol. 1982 Jul;33(4):371–377. doi: 10.1016/s0009-9260(82)80297-3. [DOI] [PubMed] [Google Scholar]
  21. Graham A., Kalsheker N. A., Newton C. R., Bamforth F. J., Powell S. J., Markham A. F. Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion) and PiI (Arg39----Cys). Hum Genet. 1989 Dec;84(1):55–58. doi: 10.1007/BF00210671. [DOI] [PubMed] [Google Scholar]
  22. Hodgson I., Kalsheker N. DNA polymorphisms of the human alpha 1 antitrypsin gene in normal subjects and in patients with pulmonary emphysema. J Med Genet. 1987 Jan;24(1):47–51. doi: 10.1136/jmg.24.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hubbard R. C., Sellers S., Czerski D., Stephens L., Crystal R. G. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA. 1988 Sep 2;260(9):1259–1264. [PubMed] [Google Scholar]
  24. Janus E. D., Phillips N. T., Carrell R. W. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet. 1985 Jan 19;1(8421):152–154. doi: 10.1016/s0140-6736(85)91916-6. [DOI] [PubMed] [Google Scholar]
  25. Jeppsson J. O., Franzén B. Typing of genetic variants of alpha 1-antitrypsin by electrofocusing. Clin Chem. 1982 Jan;28(1):219–225. [PubMed] [Google Scholar]
  26. Kolodka T. M., Finegold M., Kay M. A., Woo S. L. Hepatic gene therapy: efficient retroviral-mediated gene transfer into rat hepatocytes in vivo. Somat Cell Mol Genet. 1993 Sep;19(5):491–497. doi: 10.1007/BF01233254. [DOI] [PubMed] [Google Scholar]
  27. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978;204(5):345–351. doi: 10.1111/j.0954-6820.1978.tb08452.x. [DOI] [PubMed] [Google Scholar]
  28. Le A., Graham K. S., Sifers R. N. Intracellular degradation of the transport-impaired human PiZ alpha 1-antitrypsin variant. Biochemical mapping of the degradative event among compartments of the secretory pathway. J Biol Chem. 1990 Aug 15;265(23):14001–14007. [PubMed] [Google Scholar]
  29. Lieberman J., Winter B., Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. doi: 10.1378/chest.89.3.370. [DOI] [PubMed] [Google Scholar]
  30. Lomas D. A., Evans D. L., Finch J. T., Carrell R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
  31. Lomas D. A., Finch J. T., Seyama K., Nukiwa T., Carrell R. W. Alpha 1-antitrypsin Siiyama (Ser53-->Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem. 1993 Jul 25;268(21):15333–15335. [PubMed] [Google Scholar]
  32. McNeil T. F., Sveger T., Thelin T. Psychosocial effects of screening for somatic risk: the Swedish alpha 1 antitrypsin experience. Thorax. 1988 Jul;43(7):505–507. doi: 10.1136/thx.43.7.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Michael S. I., Curiel D. T. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther. 1994 Jul;1(4):223–232. [PubMed] [Google Scholar]
  34. Potempa J., Korzus E., Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994 Jun 10;269(23):15957–15960. [PubMed] [Google Scholar]
  35. Propst T., Propst A., Dietze O., Judmaier G., Braunsteiner H., Vogel W. High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin deficiency and chronic liver disease. Ann Intern Med. 1992 Oct 15;117(8):641–645. doi: 10.7326/0003-4819-117-8-641. [DOI] [PubMed] [Google Scholar]
  36. Propst T., Propst A., Dietze O., Judmaier G., Braunsteiner H., Vogel W. Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. J Hepatol. 1994 Dec;21(6):1006–1011. doi: 10.1016/s0168-8278(05)80609-9. [DOI] [PubMed] [Google Scholar]
  37. Schwartz J. Air pollution and hospital admissions for the elderly in Detroit, Michigan. Am J Respir Crit Care Med. 1994 Sep;150(3):648–655. doi: 10.1164/ajrccm.150.3.8087333. [DOI] [PubMed] [Google Scholar]
  38. Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994 Jul;49(7):695–698. doi: 10.1136/thx.49.7.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Seersholm N., Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):369–373. doi: 10.1164/ajrccm.151.2.7842193. [DOI] [PubMed] [Google Scholar]
  40. Shaheen S. O., Barker D. J., Holgate S. T. Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 1995 May;151(5):1649–1652. doi: 10.1164/ajrccm/151.5_Pt_1.1649. [DOI] [PubMed] [Google Scholar]
  41. Sharp H. L., Bridges R. A., Krivit W., Freier E. F. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med. 1969 Jun;73(6):934–939. [PubMed] [Google Scholar]
  42. Shin M. S., Ho K. J. Bronchiectasis in patients with alpha 1-antitrypsin deficiency. A rare occurrence? Chest. 1993 Nov;104(5):1384–1386. doi: 10.1378/chest.104.5.1384. [DOI] [PubMed] [Google Scholar]
  43. Silverman E. K., Province M. A., Campbell E. J., Pierce J. A., Rao D. C. Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus. Hum Hered. 1990;40(6):340–355. doi: 10.1159/000153958. [DOI] [PubMed] [Google Scholar]
  44. Snider G. L. Emphysema: the first two centuries--and beyond. A historical overview, with suggestions for future research: Part 2. Am Rev Respir Dis. 1992 Dec;146(6):1615–1622. doi: 10.1164/ajrccm/146.6.1615. [DOI] [PubMed] [Google Scholar]
  45. Stockley R. A., Morrison H. M., Kramps J. A., Dijkman J. H., Burnett D. Elastase inhibitors of sputum sol phase: variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment. Thorax. 1986 Jun;41(6):442–447. doi: 10.1136/thx.41.6.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Sveger T., Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology. 1995 Aug;22(2):514–517. doi: 10.1002/hep.1840220221. [DOI] [PubMed] [Google Scholar]
  47. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976 Jun 10;294(24):1316–1321. doi: 10.1056/NEJM197606102942404. [DOI] [PubMed] [Google Scholar]
  48. Tobin M. J., Cook P. J., Hutchison D. C. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest. 1983 Jan;77(1):14–27. doi: 10.1016/0007-0971(83)90002-5. [DOI] [PubMed] [Google Scholar]
  49. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  50. Wall M., Moe E., Eisenberg J., Powers M., Buist N., Buist A. S. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr. 1990 Feb;116(2):248–251. doi: 10.1016/s0022-3476(05)82882-3. [DOI] [PubMed] [Google Scholar]
  51. Wright J. L., Hobson J. E., Wiggs B., Pare P. D., Hogg J. C. Airway inflammation and peribronchiolar attachments in the lungs of nonsmokers, current and ex-smokers. Lung. 1988;166(5):277–286. doi: 10.1007/BF02714058. [DOI] [PubMed] [Google Scholar]
  52. Wu M. C., Eriksson S. Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ. J Clin Epidemiol. 1988;41(12):1157–1165. doi: 10.1016/0895-4356(88)90019-4. [DOI] [PubMed] [Google Scholar]
  53. Yoshida A., Lieberman J., Gaidulis L., Ewing C. Molecular abnormality of human alpha1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1324–1328. doi: 10.1073/pnas.73.4.1324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Yu M. H., Lee K. N., Kim J. The Z type variation of human alpha 1-antitrypsin causes a protein folding defect. Nat Struct Biol. 1995 May;2(5):363–367. doi: 10.1038/nsb0595-363. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES